Clinical characteristics and medication prescription at the time of coronary function testing, grouped according to final clinical diagnosis
| Characteristics | MVA (n=78) | VSA (n=25) | Mixed MVA and VSA (n=31) | Non-cardiac symptoms (n=17) | P value |
| Age (years) | 62 (IQR 53–68) | 54 (IQR 51–65) | 63 (IQR 58–70) | 58 (IQR 52–65) | 0.085 |
| Sex (female) | 60/78 (76.9%) | 15/25 (60.0%) | 22/31 (71.0%) | 14/17 (82.4%) | 0.316 |
| Smoking history | 29/78 (37.2%) | 14/25 (56.0%) | 18/31 (58.1%) | 2/17 (11.8%) | 0.009 |
| Hypertension | 53/78 (67.9%) | 11/25 (44.0%) | 21/31 (67.7%) | 11/17 (64.7%) | 0.180 |
| Diabetes mellitus | 11/78 (14.1%) | 7/25 (28.0%) | 5/31 (16.1%) | 6/17 (35.3%) | 0.132 |
| Atrial fibrillation | 5/78 (6.4%) | 1/25 (4.0%) | 3/31 (9.7%) | 0/17 (0.0%) | 0.739 |
| Previous MI | 8/78 (10.3%) | 5/25 (20.0%) | 10/31 (32.3%) | 1/17 (5.9%) | 0.026 |
| Previous PCI | 7/78 (9.0%) | 5/25 (20.0%) | 7/31 (22.6%) | 0/17 (0.0%) | 0.052 |
| Previous CVA | 9/78 (11.8%) | 5/25 (20.0%) | 4/31 (12.9%) | 2/17 (11.8%) | 0.728 |
| Peripheral arterial disease | 3/78 (3.8%) | 3/25 (12.0%) | 2/31 (6.5%) | 0/17 (0.0%) | 0.301 |
| Cholesterol (mmol/L) | 3.28 (2.78–4.10) | 3.12 (2.73–3.78) | 3.34 (2.82–4.35) | 3.81 (2.94–4.27) | 0.317 |
| Triglycerides (mmol/L) | 0.79 (0.60–1.19) | 0.82 (0.49–1.29) | 0.88 (0.64–1.56) | 1.07 (0.63–1.30) | 0.587 |
| HDL (mmol/L) | 1.11 (0.94–1.41) | 1.03 (0.81–1.40) | 1.13 (0.95–1.41) | 1.10 (0.95–1.39) | 0.634 |
| ASSIGN cardiovascular risk score | 17 (10–33) | 12 (9–39) | 24 (17–28) | 16 (12–46) | 0.285 |
| Statin prescription | 67/78 (85.9%) | 20/25 (80.0%) | 27/31 (87.1%) | 12/17 (70.6%) | 0.395 |
| Aspirin prescription | 67/78 (85.9%) | 22/25 (88.0%) | 29/31 (93.5%) | 13/17 (76.5%) | 0.429 |
| P2Y12 inhibitor prescription | 9/78 (11.5%) | 3/25 (12.0%) | 6/31 (19.4%) | 3/17 (17.6%) | 0.660 |
| Anticoagulant prescription | 3/78 (3.8%) | 1/25 (4.0%) | 2/31 (6.5%) | 1/17 (5.9%) | 0.832 |
| Beta-blocker prescription | 48/78 (61.5%) | 15/25 (60.0%) | 27/31 (87.1%) | 11/17 (64.7%) | 0.047 |
| RAAS blocker prescription | 34/78 (43.6%) | 10/25 (40.0%) | 14/31 (45.2%) | 10/17 (58.8%) | 0.664 |
Mann-Whitney U test or Fisher’s Exact test was applied according to variable types. All values are reported as median (IQR) or n (%).
CCB, calcium-channel blocker; CVA, cerebrovascular accident; MI, myocardial infarction; MVA, microvascular angina; PCI, percutaneous coronary intervention; RAAS, renin-angiotensin–aldosterone system; VSA, vasospastic angina.